Maintenance of Response With Certolizumab Pegol for the Treaatment of Chronic Plaque Psoriasis: Results of a 32-Week Re-Randomized Maintenance Period from an Onging Phase 3, Multicenter, Randomized, Active- and Placebo-Controlled Study (CIMPACT). J of Skin 2017, 1 (3.1), s24. https://doi.org/10.25251/skin.1.supp.23.